Covidien Recalls Syringes With Chinese-Produced Heparin
This article was originally published in PharmAsia News
Executive Summary
Covidien announced a recall of its pre-filled syringes containing heparin, citing the same contamination possibility involved in recalls of the drug itself. Covidien, formerly Tyco Healthcare, said it acted after being notified by Scientific Protein Laboratories the China-produced heparin in the syringes also contained a contaminant blamed for deaths of patients receiving the blood-clotting drug. The voluntary Covidien recall was announced in conjunction with the U.S. FDA. (Click here for more
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.